ArticleCancer reports (Hoboken, N.J.)2024

Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy.

Page E Blas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.